RxDoctor Payments Data

Steve Pierpaoli, MD

Urology · Chicago Ridge, ILNPI 1891751566

Payments from drug & device makers

$7,375in general payments, 2019–2025

Across 345 payments — averaging $21.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$1K
  • Medtronic$992
  • AbbVie$543
  • Boston Scientific$451
  • Astellas Pharma US Inc$366
  • Urovant Sciences Inc$321
  • plus $3K from 43 others

What the payments were for

  • Travel & lodging$85412%
  • Food & beverage$6,28085%
  • Education$2413%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,375 in reported general payments places this provider in the 70th percentile of 550 urology providers in Illinois.

See all urology providers in Illinois

Medicare billing

Part B allowed, 2024
$792,733
Medicare patients
1,367
Services billed
20,906

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron129$106,332
MyrbetriqMirabegron127$96,428
Tamsulosin Hcl754$10,760
Potassium Citrate ErPotassium Citrate92$8,183
Finasteride401$5,128
Bethanechol Chloride73$4,147
Methenamine Hippurate74$3,660
Silodosin40$3,205
Estradiol31$2,516
Testosterone Cypionate29$2,055
Solifenacin Succinate41$1,246
Alfuzosin Hcl ErAlfuzosin Hcl62$1,168
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst91$842
Chlorthalidone31$565
Bicalutamide13$486

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$1,264$106,332129 claims
Astellas Pharma US IncMyrbetriq$366$96,428127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 550 urology providers in Illinois.

Other urology in Chicago Ridge

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →